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Current smallpox vaccines are live vaccinia viruses that replicate in the vaccinee inducing immunity against the deadly disease smallpox.
Replication resulting in virus spread within the host, however, is the major cause of severe postvaccinal adverse events. Therefore, attenuated
strains such as modified vaccinia Ankara (MVA) or LC16m8 are candidates as next generation vaccines. These strains are usually grown in
primary cells in which mass production is difficult and have an unknown protective potential in humans. Proven vaccine strains of defined
origin and modern production techniques are therefore desirable. In this study, defective vaccinia virus (dVV) lacking a gene essential for
replication (derived from the Lister vaccine in a complementing cell line) was compared with the Wyeth smallpox vaccine strain and with
MVA in mouse animal models using cowpox and ectromelia virus challenge. Similar to MVA, prime-boost immunizations with defective
vaccinia induced robust long-term immunity, suggesting it as a promising next generation smallpox vaccine.
D 2005 Elsevier Inc. All rights reserved.Keywords: Smallpox; Vaccines; Defective vaccinia; Modified vaccinia Ankara; Ectromelia; CowpoxIntroduction
The smallpox vaccines used during the global smallpox
eradication campaign were live vaccinia viruses which
needed to replicate in the vaccinated host in order to induce
protective immunity. These first generation vaccines,
although highly effective, have a certain risk of adverse
events including mortality. They were produced under
nonsterile conditions on animal skin, had a defined bacterial
bioburden and were administered by skin scarification
(Henderson and Moss, 1999). Second generation vaccines,
produced from cloned vaccinia in cell culture (Weltzin et al.,
2003), are free from bacterial contamination but still
replicate in the host and are expected to have a similar
spectrum of side effects. Vaccine stocks of first and second
generation vaccines were built up for emergency situations
such as bioterrorism (Henderson et al., 1999).0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.06.043
* Corresponding author. Fax: +43 1 20100 4000.
E-mail address: falknef@baxter.com (F.G. Falkner).Since increasing parts of the world population are
weakened by acquired or inherited immune deficiencies,
by immune suppressive drugs (after cancer therapy or organ
transplant) or, as a further risk factor, suffer atopic dermatitis
(Engler et al., 2002), safer smallpox vaccines without the
known serious side effects are needed. More attenuated
vaccinia viruses were developed earlier, among them
modified vaccinia Ankara (MVA) by serial passage in
primary chicken cells (Mayr et al., 1978), LC16m8 or
derivates in primary rabbit cell cultures (Kidokoro et al.,
2005; Sugimoto and Yamanouchi, 1994) or NYVAC by
deletion of many nonessential genes (Tartaglia et al., 1992).
All these vaccines are grown in primary cells, a difficult
production substrate in the industrial scale. In addition,
using primary cells, there is a constant contamination risk
with adventitious viruses and bacteria requiring excessive
quality control programs.
To overcome these shortcomings, we have investi-
gated the protective potential of genetically disabled
smallpox vaccines growing in permanent production cell05) 91 – 101
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was made by deleting an essential gene encoding the
enzyme uracil –DNA–glycosylase (UDG) from the
Elstree/Lister vaccine strain (Holzer and Falkner, 1997;
Ober et al., 2002), widely used in the smallpox
eradication campaign (Henderson and Moss, 1999). The
UDG enzyme is required for viral replication; its deletion
renders the virus replication incompetent, however, it still
allows infection and early gene expression (Holzer and
Falkner, 1997). The permanent cell line, in which the
virus can multiply, is genetically modified and supplies
this enzyme in trans. In this report, we show that
defective vaccinia, similar to MVA, induces robust long-
term immunity in animal models relevant for smallpox
vaccine development including challenge with cowpox
virus or ectromelia virus. The results of this study can
help in the development of a next generation smallpox
vaccine that fulfils the requirements of safety and
efficacy, originating from a proven vaccine strain and
feasibility of large scale production.Results
Defective vaccinia protects mice against lethal challenge
with cowpox virus
Efficacy studies of candidate smallpox vaccines are
performed in animal models because challenge studies
with variola virus in humans cannot be performed. One of
the relevant animal models in smallpox vaccine develop-
ment is intranasal (i.n.) infection of the mouse with
cowpox virus (CPV). CPV has the most ancient genome
among the orthopoxviruses, is highly virulent for mice,
however, there is an age dependent susceptibility of mice
against CPV; the LD50 in young Balb/c mice (10–12 g
body weight) is 5  104 pfu, older mice are less
susceptible and a challenge dose of 2  106 pfu usually
kills around 50% (Bray et al., 2000). CPV may also cause
death in humans (Eis-Hubinger et al., 1990). This virus (or
a CPV-like virus) may be considered to be the ancestor of
vaccinia or variola virus (Shchelkunov et al., 1998).
The CPV challenge model was therefore used to evaluate
the experimental vaccine dVV-L in comparison with MVA,
both replication-deficient in humans. The dVV-L vaccine
was derived from the Elstree/Lister vaccine strain by
deleting the gene encoding the enzyme UDG via recombi-
nation followed by five plaque purifications and the
passages required to grow up a large virus stock (Ober et
al., 2002). The MVA isolate used was originally obtained
from A. Mayr as MVAII/85 in passage 575. The replication-
competent vaccine included into the comparison is derived
from the Wyeth strain used in the Dryvax vaccine licensed
in the United States.
In the initial experiments, escalating doses of MVA or
dVV-L were injected into Balb/c mice. Doses in the rangeof 104 to 107 plaque forming units (pfu) per animal of
dVV-L or MVA were given by intramuscular injection.
Three weeks later, the mice were challenged intranasally
with 2  106 pfu of cowpox virus. Body weight and
clinical illness were monitored daily. Both nonreplicating
viruses, dVV-L and MVA, did not protect at a dose of 104
pfu per animal (not shown). Protection (previously defined
as <3% weight loss; Belyakov et al., 2003) started at
doses of 1  106 pfu per animal, and robust protection
was obtained with doses 1  106 pfu (Fig. 1).
Unimmunized mice challenged with CPV dramatically
lost weight. In our hands, all challenged control mice got
seriously sick and after having lost >25% p3 of the body
weight were sacrificed to prevent suffering. Based on the
protection data, a standard vaccination dose of 1  106
pfu per mouse of either dVV-L or MVA was chosen in
further immunizations. Surprisingly, dVV-L, though repli-
cation-incompetent and restricted to early gene expression,
was fully protective in the short-term CPV challenge
model.
Boosting is required for robust long-term protection and
high antibody levels
In humans vaccinated once by scarification with a
replicating vaccinia virus, humoral and T cell immunity
is long lasting (Hammarlund et al., 2003). To approach
this question also for the nonreplicating viruses dVV-L
and MVA, mice were either immunized once or twice
i.m. with a dose of 1  106 pfu, the dose shown to be
protective in the short-term experiments. The time
interval between the prime and boost immunizations
was 3 weeks. The animals were challenged 90 days later
with a dose of 2  106 pfu CPV per animal. As
expected, a single dose of the Wyeth control virus, given
i.m., induced good long-term protection after challenge
with CPV (Fig. 2A), while the nonreplicating vaccines,
including dVV-L and MVA, did not protect completely.
A single dose was not sufficient for full protection.
Boosting the immune response with a second dose
improved protection significantly (Fig. 2B), weight loss
was now minimal for both nonreplicating viruses. Robust
protection was also seen with the Wyeth control,
whereas all unimmunized mice challenged with CPV
lost weight and mock-challenged mice had normal
weight development.
To link protection with humoral immunity, serum
samples taken at day 0 (pre-immune), day 20 (pre-boost),
and day 90 (pre-challenge) were analyzed for vaccinia
binding antibodies by ELISA and for neutralizing anti-
bodies by a standard vaccinia virus neutralization (NT)
assay. This assay measures the neutralization of intra-
cellular mature virus (IMV) which constitutes the
majority of virus progeny and against which potent
neutralizing activity is usually induced during vaccina-
tion. Vaccination with a single dose of the Wyeth strain
Fig. 1. Short-term protection of mice after intramuscular injection of a single vaccine dose and intranasal challenge with cowpox virus (CPV). Groups of mice
(n = 6) were intramuscularly vaccinated with 105 (A), 106 (B) and 107 (C) pfu of the indicated viruses. Three weeks later, animals were intranasally challenged
with 2  106 pfu of CPV. Individual weights of mice were monitored over 12 days and expressed as means for each group. The dotted line indicates the
protective levels (3% weight loss). Unimmunized mock-challenged (mock chall) and unimmunized CPV challenged (CPV chall) mice served as controls. The
data are representative for two independent experiments. Mean values T standard errors of mean (SEM) within groups for each time point of monitoring of two
independent experiments are presented ( P < 0.001).
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20 that did not increase significantly until day 90 (Table
1A). NT titers measured at day 20 increased significantly
up to the challenge date at day 90 correlating with
protection. The dVV-L vector induced low levels of
ELISA antibodies that increased slightly until day 90. In
parallel, NT antibodies, undetectable at day 20, could be
measured at the later time point. In contrast, a single i.m.
dose of MVA was barely sufficient to induce measurable
ELISA antibodies and also NT antibodies remained low
or even below the detection limit.
Using the prime-boost protocol, ELISA antibodies
levels increased several-fold compared to the single
immunizations (Table 1B). The day 90 sera had also a
high IMV neutralizing activity. With MVA, boosting
resulted now in easily measurable, albeit low, levels of
ELISA antibodies and also in good neutralizing activities.
A strong increase in ELISA titer after boosting was noted
with dVV-L that went parallel with good neutralizing
activity reflected in the protection results. After challenge,
ELISA antibodies increased in all groups to average
values of 17 Ag/ml, and NT antibodies reached titers up
to 8000–16,000 (not shown), suggesting that no steriliz-
ing immunity was achieved by the vaccines in the
intranasal CPV challenge model. In the pre-immune sera,
no vaccinia-specific antibodies were detectable.Comet inhibition after vaccinations
Neutralizing activities against extracellular enveloped
virus (EEV), the minor fraction of virus progeny, that is
responsible for long-range dissemination of cell-free poxvi-
ruses can be assessed by comet inhibition assays (Law and
Smith, 2001). The comet inhibition assays were performed
with the mouse antisera described above (used in a 1:50
dilution) obtained after the single or double vaccinations
with 1  106 pfu of dVV-L, MVA and Wyeth. A rabbit anti-
vaccinia hyperimmune serum, raised against live WR virus,
served as positive control. While this control antiserum fully
inhibited comets induced by the IHD-J strain, no significant
inhibition could be observed with the mouse antisera (data
not shown).
Since anti-comet activity measurable in 1:50 diluted
antiserum seems to be induced at higher vaccination doses
(two vaccinations with a hundred-fold higher dose of MVA
were used previously to show comet inhibition; Wyatt et al.,
2004), we immunized mice with MVA and dVV-L with 1 
108 pfu (two vaccination with a 3-week interval), collected
sera 4 weeks after the boost and assayed the sera. The
Wyeth strain was included, however, at a dose of 1  107
pfu (due to the low concentration of the vaccine preparation,
the 108 pfu dose could not be used). This time, reduction of
comets could be observed with the sera of all five of the
Table 2
Anti-comet activity in mouse sera after prime-boost immunizations at
elevated vaccination doses
Immunization Mouse Comet inhibitiona
Pre-immune
Wyeth (1  107 pfu/i.m.)
Allb 0
1 + +
2 + +
3 0
4 0
5 0
dVV-L (1  108 pfu/i.m.) 1 + + +
2 + + +
3 + + +
4 + + +
5 + + +
MVA (1  108 pfu/i.m.) 1 + + +
2 + + +
3 + +
4 +
5 + +
Rabbit r-aVVc – + + +
a Degrees of comet inhibition: + + +, full; + +, intermediate; +, some; 0,
no inhibition.
b Sera of all mice were negative.
c 1:800 dilution of r-aVV #Imm320KP100504.
Fig. 2. Long-term protection of mice after single and prime-boost
immunizations with the indicated viruses and intranasal CPV challenge.
(A) Groups of mice (n = 6) were intramuscularly immunized at day 0 with
a single dose of 106 pfu the viruses Wyeth, dVV-L or MVA-WT. (B)
Immunizations according to a prime-boost protocol (first immunization at
day 0, boost with the same dose of the same viruses at day 21). Ninety
days after the first immunization, intranasal challenge was performed with
2  106 pfu CPV. Unimmunized mock-challenged (mock chall) and
unimmunized CPV challenged (CPV chall) mice served as controls.
Individual weights of mice were monitored over 10 days and expressed as
means for each group. Mean values T standard errors of mean within
groups for each time point of monitoring of two independent experiments
are presented (P < 0.001). For symbols, see legend of Fig. 1.
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vaccinated mice. In the Wyeth control, reduction was also
obtained, however, to a lower extent (Table 2). This result isTable 1
Antibody responses in immunized mice
A ELISA (Ag/ml)a NT-50b
Single dose Day 20 Day 90 Day 20 Day 90
None <0.1 <0.1 <25 <25
Wyeth 3.99 T 0.50 4.77 T 0.57 100 T 30.5 882.5 T 164.9
dVV-L 0.62 T 0.50 1.41 T 0.20 <25 686 T 141.1
MVA-WT <0.15 <0.15 <25 <25
B ELISA (Ag/ml) NT-50
Prime-boost Day 90 Day 90
None <0.1 <25
Wyeth 9.33 T 0.90 1407 T 395.0
dVV-L 6.91 T 0.90 1927 T 24.8
MVA-WT 1.67 T 0.72 1354 T 22.3
a Pooled sera per group (n = 6) were analyzed, and mean values T SEM of
two independent experiments are shown.
b Calculated according to Langford et al. (1981).consistent with the protection results obtained so far with
the vaccine preparations.
The nonreplicating vectors induce long-lasting
vaccinia-specific T cell responses
To learn more about cellular immune effector mecha-
nisms after vaccination with defective vaccinia, we also
determined the amount of IFN-g producing spleen cells after
the immunizations by enzyme-linked immunospot (ELI-
SPOT) assays. Under the chosen experimental conditions,
this assay monitors mainly the secretion of IFN-g by
activated CD8+ T cells. Mice (3 per group) were immunized
i.m. with 1  106 pfu of the nonreplicating viruses, either
with a single dose or by prime-boost injection. The Wyeth
strain was given by scarification. Spleens were harvested at
day 8 (around the expected peak of T cell activity after the
first injection), after day 30 (the expected peak several days
after the boost vaccination) and 90 days. Total spleen cells
were then stimulated with vaccinia virus ex vivo and
incubated in the ELISPOT plates. As shown in Fig. 3, the
highest number of IFN-g producing T cell was seen at day 8
after the first immunization. All three viruses induced
approximately equal amounts of spot forming cells (SFC).
Without further boosting, levels decreased by day 30 and
remained more or less constant until day 90. A boost
injection with MVA or dVV-L at day 21 resulted in a strong
elevation of T cells (measured at day 30) and decreasing
only slightly until day 90. Interestingly, a second scarifica-
tion with the replicating virus had no strong impact on T cell
levels. A single scarification dose usually results in long-
term protection. Presumably, the live virus administered via
a second scarification does not multiply and thus not boost
Fig. 3. ELISPOT assays measuring IFN-g-producing lymphocytes in the
spleen of immunized mice. Groups of mice (n = 3) received single and
prime-boost intramuscular immunizations at day 0 and day 21, respec-
tively, with the indicated viruses as described in the legend of Fig. 2. The
Wyeth strain was given by scarification. Pooled splenocytes of three mice
per group were harvested at days 8, 30 and 90 post vaccinations.
Unimmunized animals were used as controls (not shown). SFC data are
mean values (TSEM) of two independent experiments.
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defective vaccinia correlated not only with high neutralizing
antibody levels but also with elevated numbers of IFN-g
inducible T cells. Thus, antibodies and T cells contribute toFig. 4. Protection studies in B- and T-cell-deficient mice. (A) B-cell-deficient mice
single dose of the indicated viruses and challenged 3 weeks later with 2  106 pfu
challenged as described above. (C) Long-term protection of Jh mice. Mice (n = 3)
boosted at day 21 and intranasally challenged with 2  106 pfu CPV 90 days afte
unimmunized CPV challenged (CPV chall) mice (n = 3) served as controls. Indiv
each group. Mean values T standard errors of mean within groups for each time p
were less than or equal to 0.002 using B-cell-deficient mice (A, C) and 0.9 in sho
control mice died at day 7 (A, B) and two at day 10 (C) (indicated by crosses),the robust long-term protection induced by the nonreplicat-
ing vaccinia vectors.
Protective role of dVV and MVA in B-cell- and
T-cell-deficient mice
MVA has previously been shown to protect immune-
deficient mice in the WR challenge model (Wyatt et al.,
2004). To confirm that defective vaccinia protects by similar
immune mechanisms and extend the findings on long-term
protection, we determined the role of B and T cells in
protection from CPV challenge. B-cell-deficient mice (Jh
knock-out mice, unable to produce antibodies with normal T
cell development; Chen et al., 1993) and T-cell-deficient
mice were immunized once i.m. with 1  106 pfu of the
nonreplicating viruses and challenged 21 days later intra-
nasally with CPV. While the B-cell-deficient mice were
protected from severe weight loss (Fig. 4A) with both
viruses, the T-cell-deficient mice rapidly lost weight and
died (Fig. 4B). Therefore, for short-term protection, T cells
were sufficient, while B-cells including antibodies were not
required. Three weeks after the challenge, one of the MVA
vaccinated B-cell-deficient mice, though protected from
weight loss, showed typical cutaneous pox lesions on skin,(Jh mice, n = 3) were intramuscularly immunized at day 0 with 106 pfu of a
of CPV. (B) T-cell-deficient mice (nude mice, n = 3) were vaccinated and
were intramuscularly immunized at day 0 with 106 pfu of indicated viruses,
r the first immunization. Unimmunized mock-challenged (mock chall) and
idual weights of mice monitored over 10 days and expressed as means for
oint of monitoring of two independent experiments are presented. P values
rt-term protection with T-cell-deficient mice (B). Two of the nonvaccinated
the third mouse was euthanized when 25% weight loss had occurred.
S. Coulibaly et al. / Virology 341 (2005) 91–10196paws and tail (not shown), suggesting that the cellular
immune responses while protecting from severe disease
could not clear the virus.
To complete the picture, B-cell-deficient Jh mice were
immunized with MVA and dVV using the prime-boost/long-
term protection protocol and challenged 90 days later with
CPV. Surprisingly, while controls lost weight and died, the
vaccinated mice were partially protected, the weight loss
was in the 5–10% range (Fig. 4C). At the end of the
monitoring period, the spleens of the B-cell-deficient mice
were assayed for IFN-g producing vaccinia-specific T cells
by ELISPOT assays. As expected, relatively high levels of
vaccinia-specific T cells were present explaining the good
protection results, while in the controls, no vaccinia-specific
T cells were detectable (data not shown). Thus, MVA and
dVV induce a similar immune response in protection from
CPV challenge. Surprisingly, there was also some protection
in the long-term experiment confirming the important role
of T cells in poxviral immunity.
Protection of mice against ectromelia virus (EV) infection
The ectromelia model is a further important model to
assess efficacy of smallpox vaccines. Infectious ectromelia
is an orthopoxvirus infection of mice that is usually
accompanied by severe pneumonia and hepatitis and high
mortality (Fenner, 1981). Genetically susceptible Balb/c
mice are killed by low intranasal doses of the virulent strainsFig. 5. Protection of mice after intramuscular injection of a single vaccine dose a
intramuscularly vaccinated with 106 (A), 107 (B) and 108 (C) pfu of the indicated v
of EV. Individual weights of mice monitored over 11 days and expressed as mean
loss). Unimmunized mock-challenged (mock chall) and unimmunized EV challen
mice died at days 6 and 7 (indicated by crosses), the last mouse was euthanized w
point of monitoring is indicated ( P = 0.02, P = 0.03 and P < 0.001 for 106 (A), 107
repeated once with similar results.within 7 days (Jacoby and Bhatt, 1987). The EV Moscow
strain was chosen for challenge as it is the most virulent
among the so far characterized strains and shares important
orthopoxviral genes (Chen et al., 2003). The intranasal route
was chosen to get comparative results to the similarly
designed cowpox challenge experiments. Previous experi-
ments showed that the lethal dose 50 for Balb/c mice is <10
pfu per animal and that the mortality curve increases steeply
with dose (S.C. unpublished). Based on these results, a
challenge dose of 125 pfu was chosen.
In order to compare dVV-L, MVA and the Wyeth strain
in this model, Balb/c mice were vaccinated once with
increasing doses (range 1  106 to 1  108 pfu per animal)
with the vaccines and challenged 3 weeks later intranasally
with the Moscow strain. The challenge dose of 125 pfu EV
per animal overwhelmed immunity induced by the lower
vaccination doses. After vaccination with 1  106 pfu/
animal, the dose protecting from cowpox infection, all
animals got sick after challenge with EV and most of them
died (Fig. 5A). The higher vaccination dose of 1  107 was
not able to prevent severe sickness in case of the Wyeth
strain but was protective in case of dVVand MVA (Fig. 5B).
With the highest dose of 1  108 pfu/animal, robust
protection was achieved with MVA and dVV (Fig. 5C). In
this part of the experiment, the Wyeth strain could not be
included into the comparison because the titer did not allow
injection of 1  108 in a 50 Al i.m. dose. In summary, while
it was easy to protect mice against cowpox or WRnd intranasal challenge with ectromelia virus. Groups of mice (n = 6) were
iruses. Three weeks later, animals were intranasally challenged with 125 pfu
s for each group. The dotted line indicated the protective levels (3% weight
ged (EV chall) mice served as controls. Five of the nonvaccinated control
hen 25% weight loss had occurred. The SEM within groups for each time
(B) and 108 (C) pfu of indicated viruses, respectively). The experiment was
S. Coulibaly et al. / Virology 341 (2005) 91–101 97challenge, ectromelia proved to be the most stringent model.
At least ten-fold higher doses of vaccine were required to
protect against ectromelia virus.Discussion
Next generation smallpox vaccines are needed because of
the high incidence of adverse events with the conventional
replicating vaccines. The advantage of further developing
attenuated strains already used in vaccination programs such
as MVA is their safety record in humans. MVA has been
shown previously to be safe over 100,000 vaccinated
humans, it protects animals from lethal orthopoxvirus
infection, including monkeys from variola and monkeypox
virus challenge (Drexler et al., 2003; Earl et al., 2004;
Hochstein-Mintzel et al., 1975; Mayr et al., 1978; Wyatt et
al., 2004). The virus is currently one of the best smallpox
vaccine candidates; it has been shown to protect mice also
against a highly virulent recombinant vaccinia virus
expressing murine interleukin 4 (McCurdy et al., 2004).
Nevertheless, the protective potential of MVA for smallpox
disease in humans remains unknown, the virus was used so
far as a pre-vaccine to prevent the side-effects of the
standard vaccination with the Lister strain in non-smallpox
endemic regions (Mayr et al., 1978). Furthermore, during
the long passage history, important epitopes may have been
lost. The virus was derived from the Ankara vaccine strain
by more than 570 passages during which about 15% of the
genome was deleted, and most genes suffered mutations
(Antoine et al., 1998; Meyer et al., 1991), potentially
resulting in loss of immune epitopes. In fact, a recent study
showed that MVA – while expressing most of the major
vaccinia antigens recognized by antibodies in human
vaccinia immune globulin – lacks one highly antigenic
protein (Jones-Trower et al., 2004). Loss of protective
epitopes has further been documented for the Japanese
LC16m8 vaccinia strain which lacks a membrane protein
with known neutralizing epitopes (Smith et al., 2002;
Takahashi-Nishimaki et al., 1991) (encoded by the B5R
gene) present on extracellular enveloped virus (EEV).
In general, vaccinia strains intended for use as smallpox
vaccines should ideally be derived from field-proven
vaccine strains by a minimal number of passages to avoid
immune escape (Rosenthal et al., 2001). Since deletion of an
essential gene requires only few steps and ensures that the
majority of protective epitopes present in the parental strain
are preserved, defective vaccinia, derived from the Lister
strain, fulfils this requirement. The defective virus, however,
displays major changes in gene expression in host cells. The
virus is infectious, however, has a block in late gene
expression while early genes are expressed for a prolonged
period of time (Holzer and Falkner, 1997). Fortunately,
many targets believed to be crucial including the EEV
protein B5R (Bell et al., 2004; Galmiche et al., 1999) are
expressed early and late in infection and thus may contributeto protection. Among the membrane proteins, the class of
early/late proteins further include A33R (a 23–28kDa EEV
protein), A56R (hemagglutinin), A36R and F12L, while
two, A34R and F12L, are expressed late (Smith et al.,
2002). The L1R protein, target of a potent IMV neutralizing
antibody, is expressed late in infection (Wolffe et al., 1995),
and the membrane protein D8L, target a genus specific
neutralizing antibody (Czerny et al., 1996), is also expressed
late (Niles and Seto, 1988). Furthermore, immunodominant
proteins in humans and animals including core proteins are
expressed late (Demkowicz et al., 1992). Though strong
antigenicity does not predict specific functional properties
of antibodies, the proteins present in the inoculum virus
should also contribute substantially to the immunizing
properties of defective vaccinia.
We have previously characterized antibody responses in
mice vaccinated once with dVV-L to some extent. After a
single vaccination with 1  106 pfu of dVV or MVA, low
levels of virion-specific antibodies predominantly of the
IgG2a isotype were detectable. To further characterize early
anti-vaccinia immune responses, chickens were vaccinated
with dVV-L-infected chicken cells inducing mainly anti-
bodies against early proteins. As shown in Western blots,
this antiserum stained in dVV- or MVA-infected cells, a
limited set of bands, in particular a strong double band in the
30 kDa range (Ober et al., 2002). The role of this
immunodominant early response in virus neutralization
remains to be determined. Virus neutralizing antibody
responses induced by defective vaccinia may be directed
against some of the over-expressed early proteins but also
against the structural proteins of the inoculum virus.
In this study, anti-comet activity (Law and Smith, 2001),
induced for instance by anti-B5R antibodies, was minimal
with the sera of mice immunized with MVA, dVV-L and
Wyeth at the low doses of 1  106 pfu per animal. Such
activity could be induced previously with much higher
doses of MVA (Wyatt et al., 2004), in rabbit hyperimmune
sera (Law and Smith, 2001) or by directly using B5R as an
immunogen (Galmiche et al., 1999). Immunization with
higher doses of also dVV-L resulted in strong anti-comet
activity, suggesting that the early/late proteins B5R and
A33R, as in MVA or Wyeth, are the targets for EEV
neutralization. The role of anti-B5R antibodies in protection,
however, should not be overestimated because the immuno-
logic correlate of protection from poxviral infections is
complex and redundant. The LC16m8 strain, for instance, in
which B5R is truncated by a frame shift mutation, showed
good results in humans, and even a new candidate vaccine,
the LC16m8 derivate with a genetically deleted B5R, was
fully protective in animals (Kidokoro et al., 2005).
Furthermore, new versions of genetically modified
vaccinia viruses with deletions (Jackson et al., 2005) and/
or insertions of immune modulating genes (Legrand et al.,
2005) have potential as smallpox vaccines. Moreover,
subunit vaccines consisting of multiple vaccinia outer
membrane proteins were recently shown to protect mice;
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of ten micrograms of each component were sufficient for
complete protection of a mouse (Fogg et al., 2004).
Similarly, DNA vaccines with multiple plasmids (encoding
L1, A27, B5 and A33) protect mice more efficiently than
single plasmids (Hooper et al., 2003, 2004). Since immunity
against non-live vaccines tends to be short-lived, testing of
these promising vaccines in long-term models is needed to
further evaluate their protective potential. In addition,
vaccinia replication is blocked in antigen presenting cells
(Drillien et al., 2000; Engelmayer et al., 1999), and
primarily early gene expression seems to contribute to
direct priming of the immune system by this pathway
(Coupar et al., 1986; Drillien et al., 2004). Thus, under an
optimal immunization scheme, replication including late
gene expression may not be required to prime an efficient
immune response explaining the good protection results
with defective vaccinia vectors.
The question whether dVV smallpox vaccines are safe
has been addressed recently. The safety profile of dVV
vectors in severe combined immunodeficient (SCID) mice is
similar to that of MVA (Ober et al., 2002). The question of
protectivity was addressed in this report by comparing
protective efficacy in short- and in long-term animal models.
Analysis of the immune response in the short-term mouse
models showed that antibody levels 3 weeks after a single
vaccination were low to undetectable after vaccination with
the nonreplicating vaccines. Therefore, cellular immune
responses play an important role in short-term protection
against CPV challenge, supported also by the protection of
B-cell-deficient and the rapid death of T-cell-deficient mice
after vaccination with MVA or dVV in the short-term
murine model. In the long-term mouse models, good
protection was achieved only by boosting with a second
dose and correlated with high levels of neutralizing
antibody. At the late challenge time point, also IFN-g
secreting vaccinia-specific T cells were still substantially
elevated. Interestingly, also in the long-term protection
model, B-cell-deficient mice were protected from severe
disease. Therefore, cell-mediated and humoral immune
responses contribute to good long-term protection against
poxviral infections.
Protection from ectromelia challenge was more difficult
to achieve. The standard vaccination dose of 1  106 pfu/
animal, protecting from CPV challenge, did not protect from
the comparatively low dose of 125 pfu ectromelia. In most
groups, animals lost weight and died of acute pneumonia.
Only the higher doses of MVA or dVV induced good
immunity sufficient to protect from disease.
Attenuated vaccines such as MVA or LC16m8 vaccines
are produced in primary cells. Production in primary
chicken cells of millions of doses of MVA (as required in
a recent request for proposal for MVAvaccine production by
the US government) is however a substantial challenge, not
only from the logistics of supply with primary animal cells,
but also from the viral or bacterial contamination risk. Eggshortage in avian and pandemic influenza situations might
further compromise vaccine supplies. In addition, the
relatively small production batches possible in primary cell
systems result in a huge amount of quality control samples,
raising the price per dose substantially. Since a several
hundred-fold higher dose compared to the classical small-
pox vaccine will be required for vaccination with non-
replicating vaccines, a global cost-efficient supply of a safe
nonreplicating smallpox vaccine will be difficult to achieve
with a primary cell technology. Most biologicals today are
produced in permanent cells, allowing the use of controlled
cell banks, ensuring safety from adventitious viruses and
allowing robust large-scale production. A global supply of a
safer and affordable next generation smallpox vaccine such
as defective vaccinia will therefore be dependent on the
further development of modern production techniques
including complementing production cell lines.Materials and methods
Viruses and cell lines
The Cowpox virus strain Brighton (ATCC VR-302) and
the ectromelia strain Moscow (ATCC VR-1374) were
obtained from the ATCC. The MVA strain (MVAII/85,
derived from MVA Passage 575) was obtained from A.
Mayr, Munich. MVA was grown and titered in primary
chicken embryo fibroblasts. Titration was performed using a
validated TCID50 assay. Defective vaccinia virus dVV-L
(Ober et al., 2002) is derived from the vaccinia Lister strain
(ATCC VR-862) and was titered in the complementing cell
line RK44.20 (Holzer and Falkner, 1997) by plaque assay
and neutral red staining. The New York City Board of
Health (Wyeth) strain (Wyeth Ayerst Labs, Marietta, PA)
was obtained from T. Monath, Cambridge, MA. The
replicating viruses were titered in CV-1 cells. To adjust
titers in the comparisons, TCID50 titers (TCID50/ml) were
converted to plaque titers (pfu/ml) by multiplication with the
factor of 0.5.
Mouse cowpox and ectromelia challenge models
Female Balb/c mice (6–8 weeks old) and T-cell-deficient
Balb/c nude mice (BALB/cAnNCrl-nuBR) were obtained
from Charles River. B-cell-deficient mice (JH knock-out
mice, Balb/c background) were obtained from Taconic
Farms. Mice were immunized with different doses with
0.05 ml of the indicated viruses (as described in the text).
After 21 days (short-term) or after 90 days (long-term), the
mice were challenged intranasally with 2  106 pfu by
instillation of 20 Al CPV virus suspension (diluted in PBS)
into the nares. The challenge dose of the ectromelia Moscow
strain was 125 pfu per animal. Prior to challenge, mice were
anesthetized with isoflurane (Forane, Abbott Labs). Indi-
vidual body weights and clinical symptoms were monitored
S. Coulibaly et al. / Virology 341 (2005) 91–101 99daily. The mean change in body weights as percentage of
the mean weights at the day of challenge was used in the
graphs. Mice with weight loss >25% were killed to
minimize suffering. Animal experiments were approved by
an internal animal welfare committee and were in accord-
ance with Austrian guidelines and regulations.
Vaccinia neutralization (NT) assay
Purified vaccinia virus (Wyeth strain), diluted to approx-
imately 1000 pfu/ml in DMEM/5% FBS, was incubated
with an equal volume of diluted antisera for 16 h at 37 -C.
The mixture (0.5 ml, containing approximately 100–150
pfu of input virus) was adsorbed onto CV-1 cells in six-well
plates for 1 h at 37 -C. Unbound virus and the medium
antibody mixture were replaced by fresh medium, incubated
for 3 days and stained with 0.05% crystal violet. The titers
of the antisera were determined by the reciprocal of the
highest dilution that gave 50% plaque reduction. The titers
were calculated using the formula described in Langford et
al. (1981). Mouse sera (obtained by orbital bleeding) drawn
at the time points indicated in the text were heated at 56 -C
for 30 min to inactivate complement. The standard serum
for the plaque reduction assay was a rabbit antiserum (r-
aVV #Imm320KP100504) raised against live vaccinia WR.
Vaccinia-virus-specific IgG ELISA
To determine total vaccinia-virus-specific IgG in immu-
nized mouse sera (pooled according to groups) or rabbit
sera, microtiter plates (Costar Cambridge, MA) were coated
with 100 Al/well of vaccinia virus WR/WT (Lot 589/10417,
2.5  108 pfu/ml) for 16 h at 4 -C. For standardization
purpose, additional wells were coated with goat anti-mouse
IgG (F(ab)2 (Accurate, Westbury, USA) or goat anti-rabbit
IgG. After removal of unbound antigen by washing with
PBS containing 0.05% Tween 20, pH 7.4 (PBS-T),
remaining free binding sites were blocked with 2% bovine
serum albumin (BSA) in PBS for 2 h at 37 -C. Mouse or
rabbit serum samples diluted 1:100 to 1:100,000 in 1% BSA
in PBS-T were added to vaccinia virus coated wells. A
serially diluted mouse or rabbit IgG standard preparation
(Sigma-Aldrich, Inc.) was added to wells coated with goat
anti-mouse or goat anti-rabbit IgG. The plates were
incubated for 1 h at 37 -C and, after washing, alkaline
phosphatase (AP) conjugated goat anti-mouse IgG specific
antibodies (Accurate, Westbury, NY) or AP conjugated goat
anti-rabbit IgG (Chemicon, Inc.) were added at a dilution of
1:10,000 in 1% BSA in PBS-T for a further 1 h incubation
at 37 -C. Finally, the color reaction was induced by addition
of p-nitrophenyl phosphate (PNP) substrate solution
(Sigma-Aldrich, Inc) for 30 min and stopped thereafter by
addition of 0.1 M EDTA/PBS. The plates were analyzed
with an ELISA reader (UVmax, Molecular Devices,
Sunyvale CA) at 405 nm. Antigen-specific IgG concen-
trations in serum samples were calculated by interpolatingthe corresponding OD values from the reference IgG
standard curve on the same plate.
Comet inhibition assay
This assay was performed essentially as described in Law
and Smith (2001) with the following modifications. The
IHD-J strain was diluted to a final concentration of 40 pfu/
ml, and confluent plates of CV-1 cells were infected with 0.5
ml of virus suspension in DMEM for 1 h. Cells were
washed twice with PBS, and 2 ml DMEM containing 10%
fetal calf serum and the immune sera were added and
incubated. After 2 days, plates were stained with crystal
violet. Mouse sera were used in a 1:50 dilution.
ELISPOT assay
Preparation of spleen cell suspension
Mice were sacrificed at days 8, 30 and 90 after the single
immunization and at days 30 and 90 after the prime-boost
immunization. A single cell suspension was prepared from
the pooled spleens of three animals by forcing minced
tissue through 200 mesh stainless steel sieves. Red blood
cells were depleted by incubation for 5 min at RT with a
lysis buffer containing 0.15 M NH4Cl, 10 mM KHCO3 and
0.1 M Na2-EDTA, pH 7.4, and the leukocytes were
resuspended in complete culture medium (1:1 mixture of
RPMI 1640 (Gibco, Paisley, Scotland) and Click’s medium
(Sigma, Irvine UK), supplemented with 10% fetal calf
serum, 2 mM l-glutamine, 100 IU/ml penicillin/streptomy-
cin (all from Gibco) and 50 AM 2-mercaptoethanol (Bio-
Rad, Hercules, CA).
ELISPOT assay
The frequency of specifically interferon-g secreting cells
was analyzed using a mouse IFN-g ELISPOT kit (Mabtech
AB, Nacka, Sweden) following the instructions of the
manufacturer. Briefly, polyvinylidene difluoride (PVDF)
coated 96-well plates (MAIPN4510; Millipore Corp. Bed-
ford, MA) were prewetted with 70% ethanol, washed with
PBS and coated with 100 Al/well of purified anti-IFN-g
monoclonal antibody AN-18 (Mabtech) at a concentration
of 15 Ag/ml in PBS. After overnight incubation at 4 -C, the
plates were washed with PBS, and free binding sites were
blocked by addition of 200 Al complete culture medium per
well for 2 h at 37 -C. Thereafter, the culture medium was
decanted, and serial dilutions of freshly isolated spleen cells
were added to the wells ranging from 6.0  104 to 2.5  105
cells per well. Live vaccinia virus strain WR/WT was added
at an MOI of 0.1. Wells containing no antigen or 5 Ag/ml of
Concanavalin Awere used as negative and positive controls,
respectively. The plates were then incubated for 16 h at 37
-C and 5% CO2. After overnight incubation, the cells were
discarded and the plates washed with PBS. Membrane-
bound interferon-g was detected by addition of biotinylated
IFN-g specific antibody R4-6A2 (Mabtech; 1 Ag/ml; 2 h at
S. Coulibaly et al. / Virology 341 (2005) 91–101100room temperature). After washing and subsequent addition
of streptavidin–alkaline phosphatase (Mabtech; dilution
1:1000, 1 h at room temperature), the plates were washed
again, and 100 Al BCIP/NBT (Bio-Rad, Inc.) substrate
solution was added. Spot formation was stopped after 30
min incubation at room temperature by washing extensively
in tap water. The plates were allowed to dry and the number
of spots counted using an ELISPOT reader (Mabtech,
Nacka, Sweden). The numbers of spots observed in wells
containing no antigen were subtracted from the number of
spots observed in wells containing specific antigen.
Statistical analysis
Data were analyzed with the Statistica software (version
6.0; Statsoft, Tulsa, USA); P values < 0.05 were the
criterion for statistical significance. Mouse weight data
were expressed as the mean gain/loss at different time
points of each vaccinated group and compared with the
nonvaccinated control groups using multivariate analysis
of variance (MANOVA). The GraphPad Prism software
(Version 4.0; GraphPad, Inc., San Diego, CA) was used to
prepare the figures. Vertical bars denote the 0.95%
confidence intervals.Acknowledgments
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